阿斯利康(AZN)BTK抑制剂新适应症获欧盟批准

金吾财讯
06 May

金吾财讯 | 阿斯利康(AZN)宣布,阿可替尼与苯达莫司汀和利妥昔单抗联合使用已在欧盟获得批准,用于治疗未接受过治疗且不适合接受自体干细胞移植的套细胞淋巴瘤(MCL)成年患者。新闻稿指出,这是欧盟首个也是唯一一个获批用于该适应症的BTK抑制剂。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10